An interventional study of Field expansion view in Hemianopsia, Homonymous Hemianopia and Tunnel Vision, sponsored by Massachusetts Eye and Ear Infirmary. Active, not recruiting at 1 site in United States. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.
Sponsored by Massachusetts Eye and Ear Infirmary · Not applicable, Interventional, and Basic science
The investigators are developing a new test of pedestrian hazard detection in virtual reality (VR) head-mounted display (HMD) headset, which shows virtual oncoming pedestrians in 3D while subjects are walking in real-world environment, for evaluation of visual field expansion to improve mobility in people with visual field loss.
The investigators will develop a new pedestrian hazard detection test and conduct a single arm interventional clinical trial to evaluate simulated low vision assistive devices in a sample of field loss subjects. Pedestrian detection performance with and without field expansion information will be tested and compared. The study will include 1 to 4 visits (each 2 to 4 hours) depending on the number of trials and experimental conditions (e.g., with and without simulated assistive devices) the subject is comfortable completing. The time between visits may vary depending on scheduling constraints and availability. During each visit, the subject will complete a series of simulated collision avoidance trials in VR requiring the detection and natural avoidance of a colliding pedestrian (alongside non-colliding pedestrians) while physically walking through an empty corridor. The study will be considered minimal-risk since there will be no physical obstacles that present actual collision risks.
63 studies on the registry are indexed under Hemianopsia; 24 are open to participants now.
This study's planned enrollment of 15 is below the median of 32 across 53 interventional studies indexed under Hemianopsia.
Browse Hemianopsia studies →Massachusetts Eye and Ear Infirmary is the lead sponsor of 100 studies on the registry; 23 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Various configurations of field expansion views will be additionally displayed on HMD
Other: Field expansion view
Overlaid small window on HMD to show the part of the scene in the blind field into portions of the participants' remaining, seeing, field of vision
Response time
During the pedestrian detection task, average response time to the colliding pedestrian with and without prisms
Time frame: Through study completion, an average of four months
Head movement range
During the pedestrian detection task, lateral and vertical head movement range to check the head scanning range
Time frame: Through study completion, an average of four months
Walking speed
During the pedestrian detection task, the physical walking speed of the subject
Time frame: Through study completion, an average of four months
Pedestrian detection rate
Proportion of simulated pedestrians detected (in HMD walking)
Time frame: Through study completion, an average of four months
Error rate
Proportion of false alarms and missed targets to total targets
Time frame: Through study completion, an average of four months
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts Eye and Ear Infirmary →